6 faktów, według których warto stosować siarczan chondroityny w dawce 800 mg Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2023
Słowa kluczowe:
siarczan chondroityny, choroba zwyrodnieniowa stawów, ból
##plugins.themes.bootstrap3.article.main##
Abstrakt
Pacjenci z chorobą zwyrodnieniową stawów cierpią z powodu przewlekłego bólu, ograniczenia ruchomości stawów, pogorszenia jakości życia w sensie medycznym i społecznym. Celem różnych form spersonalizowanego leczenia jest poprawa tych aspektów. Siarczan chondroityny w postaci leku, zastosowany we wczesnym okresie choroby, hamuje jej postęp, a niekiedy nawet regeneruje uszkodzone tkanki.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Słowińska, I., & Rutkowska-Sak, L. (2023). 6 faktów, według których warto stosować siarczan chondroityny w dawce 800 mg . Medycyna Faktów , 16(4(61), 311-315. https://doi.org/10.24292/01.MF.0423.03
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Martel-Pelletier J, Farran A, Montell E et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015; 20(3): 4277-89.
2. Au RYP, Au AY, Frondoza CG. Effect of different chondroitin sulfate raw materials on pro-inflammatory gene expression in chondrocytes and monocytes. 6th Symposium of ICRSI; San Diego, CA, USA, 8–11 January 2006.
3. Cantley MD, Rainsford KD, Haynes DR. Comparison of the ability of chondroitin sulfate derived from bovine, fish and pigs to suppress human osteoclast activity in vitro. Inflammopharmacology. 2013; 21(6): 407-12.
4. Klimiuk PA, Kuryliszyn-Moskal A. Choroba zwyrodnieniowa stawów. In: Puszczewicz M (ed). Reumatologia. Wielka Interna – 2016. 9th ed. Medical Tribune Polska, Warszawa: 307-29.
5. Karsdal MA, Henriksen K, Bay-Jensen ACh et al. Biomechanical markers in osteoarthritis with lessons learned from osteoporosis. Clin Exp Rheumatol. 2019; 37 Suppl 120(5): 73-87.
6. Słowińska I, Rutkowska-Sak L. Choroba zwyrodnieniowa stawów – leczenie. Praktyczna Ortopedia i Traumatologia. 2020; 3: 24-9.
7. Geenen R, Overmann C L, Christensen R et al. EULAR recommendations for the health professionals approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018; 77(6): 797-807.
8. Rausch Osthoff AK, Niedermann K, Braun J et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheuam Dis. 2018; 77(9): 1251-60.
9. Kloppenburg M, Kroon F P, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
10. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Mujsculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. Abimbola OA, Donna SC, Zhongming L et al. Analysis of Glucosamine and Chondroitin Sulfate Content in Marketed Products and the Caco-2 Permeability of Chondroitin Sulfate Raw Materials. JANA. 2020; 3(1): 37-44 .
12. Charakterystyka produktu leczniczego Cartexan 800 mg.
13. Lagnaoui R, Baumevielle M, Bégaud B et al. Less Use of NSAIDs in Long-Term than in Recent Chondroitin Sulphate Users in Osteoarthritis: a Pharmacy- based Observational Study in France. Therapie. 2006; 61(4): 341-6.
14. Reginster JY, Dudler J, Blicharski T et al. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017; 76(9): 1537-43.
15. Pelletier JP, Raynauld JP, Beaulieu AD et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016; 18(1): 256.
16. Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology. 2011; 19(6): 299-306.
17. Henrotin Y, Mathy M, Sanchez C et al. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis. 2010; 2(6): 335-48.
18. Wildi LM, Raynauld JP, Martel-Pelletier J et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011; 70(6): 982-9.
19. Singh JA, Noorbaloochi S, MacDonald R et al. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015; 1(1): CD005614. http://doi.org/10.1002/14651858.CD201601.
20. Bishnoi M, Jain A, Hurkat P et al. Chondroitin sulphate: a focus on osteoarthritis. Glycoconj J. 2016; 33(5): 693-705. http://doi.org/10.1007/s10719-016-9665-3.
21. Kompendium wiedzy o Narodowym Spisie Powszechnym Ludności i Mieszkań 2011.
22. Słowińska I, Małdyk P. Losy chorych na reumatoidalne zapalenie stawów leczonych metodą endoprotezoplastyki w obrębie stawów kończyn dolnych. Reumatologia. 2012; 50(5): 403-9. http://doi.org/10.5114/reum.2012.31399.
2. Au RYP, Au AY, Frondoza CG. Effect of different chondroitin sulfate raw materials on pro-inflammatory gene expression in chondrocytes and monocytes. 6th Symposium of ICRSI; San Diego, CA, USA, 8–11 January 2006.
3. Cantley MD, Rainsford KD, Haynes DR. Comparison of the ability of chondroitin sulfate derived from bovine, fish and pigs to suppress human osteoclast activity in vitro. Inflammopharmacology. 2013; 21(6): 407-12.
4. Klimiuk PA, Kuryliszyn-Moskal A. Choroba zwyrodnieniowa stawów. In: Puszczewicz M (ed). Reumatologia. Wielka Interna – 2016. 9th ed. Medical Tribune Polska, Warszawa: 307-29.
5. Karsdal MA, Henriksen K, Bay-Jensen ACh et al. Biomechanical markers in osteoarthritis with lessons learned from osteoporosis. Clin Exp Rheumatol. 2019; 37 Suppl 120(5): 73-87.
6. Słowińska I, Rutkowska-Sak L. Choroba zwyrodnieniowa stawów – leczenie. Praktyczna Ortopedia i Traumatologia. 2020; 3: 24-9.
7. Geenen R, Overmann C L, Christensen R et al. EULAR recommendations for the health professionals approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018; 77(6): 797-807.
8. Rausch Osthoff AK, Niedermann K, Braun J et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheuam Dis. 2018; 77(9): 1251-60.
9. Kloppenburg M, Kroon F P, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
10. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Mujsculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. Abimbola OA, Donna SC, Zhongming L et al. Analysis of Glucosamine and Chondroitin Sulfate Content in Marketed Products and the Caco-2 Permeability of Chondroitin Sulfate Raw Materials. JANA. 2020; 3(1): 37-44 .
12. Charakterystyka produktu leczniczego Cartexan 800 mg.
13. Lagnaoui R, Baumevielle M, Bégaud B et al. Less Use of NSAIDs in Long-Term than in Recent Chondroitin Sulphate Users in Osteoarthritis: a Pharmacy- based Observational Study in France. Therapie. 2006; 61(4): 341-6.
14. Reginster JY, Dudler J, Blicharski T et al. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017; 76(9): 1537-43.
15. Pelletier JP, Raynauld JP, Beaulieu AD et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016; 18(1): 256.
16. Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology. 2011; 19(6): 299-306.
17. Henrotin Y, Mathy M, Sanchez C et al. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis. 2010; 2(6): 335-48.
18. Wildi LM, Raynauld JP, Martel-Pelletier J et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011; 70(6): 982-9.
19. Singh JA, Noorbaloochi S, MacDonald R et al. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015; 1(1): CD005614. http://doi.org/10.1002/14651858.CD201601.
20. Bishnoi M, Jain A, Hurkat P et al. Chondroitin sulphate: a focus on osteoarthritis. Glycoconj J. 2016; 33(5): 693-705. http://doi.org/10.1007/s10719-016-9665-3.
21. Kompendium wiedzy o Narodowym Spisie Powszechnym Ludności i Mieszkań 2011.
22. Słowińska I, Małdyk P. Losy chorych na reumatoidalne zapalenie stawów leczonych metodą endoprotezoplastyki w obrębie stawów kończyn dolnych. Reumatologia. 2012; 50(5): 403-9. http://doi.org/10.5114/reum.2012.31399.